Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326239 | 0.94 | CNR2 (0.51) | CNR2CNR1DRD4SIGMAR1HTR4 | |
| SCHEMBL4324702 | 0.92 | CNR2 (0.64) | CNR2CNR1DRD4SIGMAR1HTR4 | |
| SCHEMBL4320289 | 0.92 | CNR1 (0.49) | CNR2CNR1DRD4SIGMAR1HTR4 | |
| SCHEMBL4325964 | 0.90 | CNR2 (0.52) | CNR2CNR1HTR4KMT2AKDM4E | |
| SCHEMBL4325256 | 0.88 | CNR1 (0.56) | CNR2CNR1 | |
| SCHEMBL4334584 | 0.87 | CNR2 (0.57) | CNR2CNR1HTR4KMT2ANPC1 | |
| SCHEMBL4326244 | 0.87 | CNR2 (0.60) | CNR2CNR1DRD4SIGMAR1KMT2A | |
| SCHEMBL4334740 | 0.86 | CNR1 (0.65) | CNR2CNR1NPC1RAB9AHSD17B10 | |
| SCHEMBL4320293 | 0.85 | CNR1 (0.57) | CNR2CNR1DRD4SIGMAR1KMT2A | |
| SCHEMBL4327319 | 0.84 | CNR2 (0.54) | CNR2CNR1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885DRD4 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.